Fused in sarcoma mislocalization is a widespread characteristic of amyotrophic lateral sclerosis


  • Nuclear-to-cytoplasmic mislocalization of unaggregated fused in sarcoma (FUS) RNA binding protein occurs through direct interaction with aberrantly retained intron 9 within the SFPQ transcript and is a widespread feature in amyotrophic lateral sclerosis (ALS).

Why this matters

  • Targeting the nuclear-to-cytoplasmic mislocalization of FUS may prove to be a useful therapeutic strategy in multiple forms of ALS.

Want to read more?

Log in or sign up to access all Neurodiem content.

Already have an account? Log In

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.